Tumor response from durvalumab (MEDI4736) + tremelimumab treatment in patients with advanced non-small cell lung cancer (NSCLC) is observed regardless of PD-L1 status
Crossref DOI link: https://doi.org/10.1186/2051-1426-3-S2-P193
Published Online: 2015-11-04
Published Print: 2015-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Rizvi, Naiyer
Chaft, Jamie
Balmanoukian, Ani
Goldberg, Sarah B
Sanborn, Rachel E
Steele, Keith E
Rebelatto, Marlon C
Gu, Yu
Karakunnel, Joyson J
Antonia, Scott
Article History
First Online: 4 November 2015